Dr. Timos Papagatsias’ Post

Thoughts on this? >> Boehringer Ingelheim, Zealand tout key fibrosis data from mid-stage MASH trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #biotech #healthcare

Thoughts on this? >> Boehringer Ingelheim, Zealand’s positive Phase 2 MASH fibrosis data ‘unintentionally’ released >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #healthcare #biotech

The Pharmabiotics Conference & Partnering event is still going strong and we want to thank all organizers, presenters, and panelists for sharing their expertise about the most innovative approaches in microbiome-specialized drug development. This year marks the 9th edition of the conference, and its theme, "An Evolving Regulatory Landscape", underscores the dynamic changes in the regulatory environment. This has been a great opportunity for gaining insights, learning about cutting-edge tools and resources, and planning for successful clinical trials in the microbiome health field. #clinicaltrials #microbiome #microbiomeresearch #pharmabiotics

Many thanks to the BEAM Alliance for inviting us to join their webinar series! In today’s session, the Swiss Round Table on Antibiotics made the case for why we need both pull and push incentives to bring new antimicrobial technologies to patients. The speakers, Rudolf Blankart, Chantal Morel, and Barbara Polek, discussed topics such as: - The antibiotic challenge: Why is the #antibiotics market far less attractive than the markets for other #pharmaceuticals? -  "Business as usual" is not an option: If we don’t find a solution to solve the major #publichealth challenge posed by #antimicrobialresistance, the costs of non-action will conceivably be enormous. - Implementation of pull incentives is gaining momentum: England and Sweden have been conducting pilot projects to test revenue guarantee models; other countries are planning to do so. In our White Paper "Effective antibiotics for the Swiss health care system: today and in the future" we suggest how a pilot project could be implemented in Switzerland to test a pull incentive-model. You will find the publication on our website: https://lnkd.in/eYVvPy_T #AMR, #globalhealth, #silentpandemic

Thoughts on this? >> Early Roche Alzheimer’s data ‘worth watching’ as long-term Leqembi, donanemab competitor >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #pharmaceutical #healthcare

It was with great enthusiasm that I read a new set of recommendations authored by alumni of the Drive-AB Consortium in a policy brief here: https://lnkd.in/dmd7ukKu It advocates for a set of antimicrobial pull incentives to be coordinated by the EU Directorate-General Health Emergency Preparedness and Response (HERA), which are both voluntary and country-specific. The objectives are both to foster antimicrobial innovation and to ensure uniform access across the EU and European Economic Area (EEA) Countries.   The framework is transparent and accountable, where the biopharmaceutical companies can see what innovations are incentivized by high, medium, low or no rewards. By tying rewards to clinical impact, innovativeness and significant reduction in mortality and morbidity, the proposal ensures that financial incentives are directed towards antimicrobial agents with the greatest potential for public benefit. It is voluntary for the EEA and EU Member States (MS) to participate, and if deciding to do so each MS will use its normal processes for pricing, reimbursement, and procurement.   Thus, COUNTRIES CAN IMPLEMENT THE SOLUTION ON THEIR OWN POLITICAL PACE USING THEIR OWN SYSTEMS. Not participating or delaying participation will deny that countries’ citizenry access to new drugs. With its capabilities and financial resources, the EU holds a significant position in coordinating a joint endeavor, and HERA seems to be the right authority to take on this task.   In Europe, only the UK and Sweden have decided to introduce similar reimbursement models at a national level so far. But there are significant advantages to having a EU wide scheme to foster antimicrobial innovation.   The message is, therefore, clear: antimicrobial pull incentives are feasible, essentially needed and have critical life-saving impact. Thanks to Christine (Larson) Årdal, Steffen Aggerholm Krog, Steffen Pierini Lüders, Kahleh Hassan, Judith Vonberg https://lnkd.in/dmd7ukKu

Thoughts on this? >> Why BARDA is handing out hundreds of millions of dollars to long-shot biotechs for Covid >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #productmarketing #pharma

💥 Join us for our first webinar of 2024 as we discuss the value of digital measures in drug development 💊🧪 with Maulik Majmudar, Ariel Dowling and Erwin De beuckelaer. 👀 We’ll take a look at insights from our latest report with Biofourmis and ask, how can we come together to ensure better utilisation of digital measures in clinical trials? During the webinar we’ll discuss: 💬 What are the biggest barriers to the adoption of digital endpoints in drug development? 💬 What is required to shift towards using digital measures as primary endpoints and supporting label claims in the future? 💬 Where does it make sense to leverage digital endpoints and for what purpose? Register now ➡️ https://lnkd.in/e5eFMVEB #drugdevelopment #digitalmeasures #digitalhealth

The rare disease market has grown consistently over the past ten years and is expected to continue to grow, however, recent barriers have emerged, including an increasing pricing pressure and emphasis on cost-effectiveness proven through comparative clinical trials. Our latest white paper delves into the current trends shaping the rare disease landscape, offering insights into emerging therapies, evolving regulatory environments, and the critical role of patient advocacy. Download your copy now to learn more: https://lnkd.in/du7bPnQJ #RareDisease #Pharma #Biotech #HealthcareInnovation #WhitePaper

Thoughts on this? >> Why BARDA is handing out hundreds of millions of dollars to long-shot biotechs for Covid >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #productmarketing #healthcare #pharma